Abevmy

In combination w/ fluoropyrimidine-based chemotherapy for patients w/ metastatic carcinoma of the colon or rectum (mCRC). In combination w/ paclitaxel for patients who have not received chemotherapy for metastatic HER2 -ve breast cancer. In combination w/ capecitabine for 1st-line treatment of patients w/ HER2 -ve metastatic breast cancer in whom treatment w/ other chemotherapy options including taxanes or anthracyclines is not considered appropriate. In combination w/ carboplatin & paclitaxel for 1st-line treatment of patients w/ unresectable, locally advanced, recurrent or metastatic non-squamous NSCLC. In combination w/ erlotinib for 1st-line treatment of patients w/ unresectable advanced, metastatic or recurrent non-squamous NSCLC w/ EGFR activating mutations. As single agent for glioblastoma after relapse or disease progression following prior therapy. In combination w/ interferon α-2a for 1st-line treatment of patients w/ advanced &/or metastatic renal cell cancer (mRCC). In combination w/ carboplatin & paclitaxel for front-line treatment of advanced (FIGO stages III B, III C & IV) epithelial ovarian, fallopian tube or primary peritoneal cancer. In combination w/ carboplatin & gemcitabine or in combination w/ carboplatin & paclitaxel for patients w/ recurrent, platinum-sensitive, epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior bevacizumab or other VEGF-targeted angiogenesis inhibitors. In combination w/ paclitaxel, topotecan or pegylated liposomal doxorubicin for patients w/ recurrent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who received no >2 prior chemotherapy regimens & who have not received prior therapy w/ bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. In combination w/ paclitaxel & cisplatin or paclitaxel & topotecan for persistent, recurrent or metastatic carcinoma of the cervix.

IV infusion mCRC 1st-line treatment: 5 mg/kg once every 2 wk or 7.5 mg/kg once every 3 wk. 2nd-line treatment: 10 mg/kg every 2 wk w/ FOLFOX-4. Patient who progressed on 1st-line bevacizumab-containing regimen 5 mg/kg every 2 wk or 7.5 mg/kg every 3 wk when used in combination w/ fluoropyrimidine-irinotecam or fluoropyrimidine-oxaliplatin based chemotherapy regimen. Metastatic breast cancer 10 mg/kg once every 2 wk in combination w/ paclitaxel; or 15 mg/kg once every 3 wk in combination w/ capecitabine. NSCLC 15 mg/kg once every 3 wk in combination w/ platinum-based chemotherapy. NSCLC w/ EGFR activating mutations 15 mg/kg once every 3 wk in combination w/ erlotinib. Malignant glioma (WHO grade IV); glioblastoma; advanced &/or mRCC 10 mg/kg once every 2 wk. Epithelial ovarian, fallopian tube & primary peritoneal cancer Front-line treatment: 15 mg/kg once every 3 wk in addition to carboplatin & paclitaxel for up to 6 cycles followed by continued use of bevacizumab as single agent until disease progression or for max of 15 mth or until unacceptable toxicity. Recurrent disease treatment: Platinum-sensitive: 15 mg/kg once every 3 wk in combination w/ carboplatin & paclitaxel for 6 cycles & up to 8 cycles followed by continued use of bevacizumab as single agent until disease progression. Platinum-resistant: 10 mg/kg once every 2 wk in combination w/ paclitaxel, topotecan (given wkly) or pegylated liposomal doxorubicin. Cervical cancer 15 mg/kg every 3 wk in combination w/ paclitaxel & cisplatin, or paclitaxel & topotecan.

Hypersensitivity to bevacizumab, Chinese hamster ovary cell products or other recombinant human or humanised Ab. Pregnancy.

Targeted Cancer Therapy

L01FG01 - bevacizumab ; Belongs to the class of VEGF/VEGFR (Vascular Endothelial Growth Factor / Receptors) inhibitors. Used in the treatment of cancer.

POM